Atomoxetine for freezing while walking

Male or female aged 18 years or older Diagnosis of idiopathic Parkinson's disease according to Movement Disorders Society Diagnostic Criteria Stabilised on optimal dopaminergic treatment for a minimum of four weeks prior to the baseline visit (Visit 1) Presence of freezing of gait symptoms on a daily basis Ability to walk for 10-meters unaided in the dopaminergic ON-state Ability to provide written informed consent in accordance with ICH-GCP and local regulations Willing and able to undergo all clinical trial assessments Current and/or previous (within 3 months) participation in a clinical trial (History of) pheochromocytoma Use of noradrenergic agents Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine) Use of high dose salbutamol (or other beta2 agonists) Pregnancy and/or breastfeeding Known hypersensitivity to atomoxetine Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker) Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments) Severe cognitive impairment hampering the ability to comply with the study protocol Active psychosis that would impact the ability to comply with the study protocol Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc > 500ms zettBa-formula) and channelopathies that would significantly compromise participant safety Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke Hepatic or renal insufficiency Narrow angle glaucoma